arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

BeyondSpring, Inc.

BYSI Health Care Biotechnology: Pharmaceutical Preparations
$0.45
▼ -9.8% Today
as of Oct 23, 11:16 ET
Last 30 days -42.34% Sep 14 → Oct 23
$0.38 $0.58 $0.78 $0.98 $1.17 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$0.59
High
$0.59
Low
$0.42
Volume
$73,021
Avg Vol
$293,626
Mkt Cap
$33M
P/E (TTM)
—
Beta
—
52w High
$2.44
52w Low
$0.42
Div Yield
—
Shares Out
$41M

Recent Press Releases & News last 60 days · 2 items

Sep 29 · 14:43 InvestorsHub
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances
Sep 29 · 11:01 PR GlobeNewswire
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

BYSI earnings at a glance

The options market is pricing a move of about ±599.3% after the report, a range of roughly -$2.25 to $3.15 from today's $0.45. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±3.1% on average; after the most recent report on May 13, 2026 it moved +4.3%. That means options currently expect more movement than BYSI has typically delivered. Implied volatility is currently 51%. The share price of $0.45 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.42
$2.44
1% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
+1.3%
50% positive
Latest IV / EM
5074%
EM ±599.3% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.56$-0.31$-0.05$0.20$0.46 Actual $-0.04Actual $-0.06Actual $-0.04Actual $-0.05Actual $-0.05 JunMar/2025Jun/2025Sep/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-7M$-5M$-3M$-747,125$1M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed May 13, 2026Mar/2026 $-0.05 — — +16.7% +4.3% earnings
Wed Nov 12, 2025Sep/2025 $-0.05 — — — — earnings
Wed Aug 13, 2025Jun/2025 $-0.04 — — — — earnings
Mon May 12, 2025Mar/2025 $-0.06 — — — -1.8% earnings
Sun Jun 30, 2024Jun 2024 $-0.04 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0$0—$0$0$0—$0
Cost of revenue————————
Gross profit————————
Operating income$-2M$-2M—$-2M$-2M$-3M—$-2M
Net income$-849,000$-7M—$-2M$-2M$1M—$-2M
EPS (diluted)————$-0.10———

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$3M$4M$8M$12M$10M$7M$3M—
Inventory————————
Total current assets$10M$14M$21M$24M$26M$32M$29M—
Total assets$15M$18M$26M$29M$31M$37M$34M—
Long-term debt————————
Total liabilities$51M$49M$50M$49M$49M$50M$49M—
Total equity$-36M$-30M$-32M$-32M$-18M$-13M$-33M$-11M

Implied volatility — last 90 days

459%3385%6310%9235%12161% Jun 22 — IV 460% · EM ±96.0%Jul 20 — IV 1758% · EM ±415.3%Aug 13 — IV 2904% · EM ±343.1%Aug 14 — IV 3697% · EM ±408.5%Aug 17 — IV 5805% · EM ±484.9%Aug 18 — IV 6834% · EM ±494.4%Aug 19 — IV 7973% · EM ±470.9%Aug 20 — IV 11472% · EM ±479.1%Aug 24 — IV 2428% · EM ±506.9%Aug 25 — IV 2443% · EM ±499.9%Aug 26 — IV 2569% · EM ±514.5%Aug 27 — IV 2950% · EM ±577.9%Aug 28 — IV 2945% · EM ±563.6%Aug 31 — IV 3411% · EM ±604.4%Sep 01 — IV 3614% · EM ±622.3%Sep 02 — IV 3723% · EM ±621.9%Sep 03 — IV 3726% · EM ±602.7%Sep 04 — IV 3883% · EM ±606.7%Sep 07 — IV 4380% · EM ±606.7%Sep 08 — IV 4639% · EM ±612.7%Sep 09 — IV 5013% · EM ±628.1%Sep 10 — IV 3974% · EM ±469.5%Sep 11 — IV 4108% · EM ±453.9%Sep 14 — IV 5592% · EM ±467.1%Sep 15 — IV 6447% · EM ±466.4%Sep 16 — IV 8361% · EM ±493.8%Sep 17 — IV 12161% · EM ±507.9%Sep 21 — IV 2297% · EM ±479.7%Sep 22 — IV 2289% · EM ±468.4%Sep 23 — IV 2530% · EM ±506.7%Sep 24 — IV 2500% · EM ±489.7%Sep 25 — IV 2420% · EM ±463.2%Sep 28 — IV 1620% · EM ±287.0%Sep 29 — IV 2432% · EM ±418.8%Sep 30 — IV 2760% · EM ±461.0%Oct 01 — IV 2658% · EM ±430.0%Oct 02 — IV 2709% · EM ±423.3%Oct 06 — IV 3773% · EM ±498.3%Oct 07 — IV 4520% · EM ±566.3%Oct 08 — IV 5074% · EM ±599.3%

Sector peers

RMTI
Rockwell Medical, Inc.
$35M $7.16+1.1%
BCTX
BriaCell Therapeutics Corp.
$35M $3.38-6.1%
VYNE
VYNE Therapeutics Inc.
$31M $28.56
ATNM
Actinium Pharmaceuticals, Inc.
$36M $1.50+8.8%
MIRA
MIRA Pharmaceuticals, Inc.
$30M $0.62-9.0%
NXTC
NextCure, Inc.
$30M $4.53-16.3%

BYSI earnings FAQ

What is BYSI's expected move for earnings?

Options currently price a move of about ±599.3%, or $2.70 per share either way from $0.45.

How does BYSI stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.1%, up 1 times and down 1 times.

What is BYSI's implied volatility?

BYSI's at-the-money implied volatility is about 51% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in